GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HAEMATO AG (HAM:HAEK) » Definitions » PE Ratio

HAEMATO AG (HAM:HAEK) PE Ratio : 9.45 (As of May. 05, 2024)


View and export this data going back to 2006. Start your Free Trial

What is HAEMATO AG PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-05-05), HAEMATO AG's share price is €17.40. HAEMATO AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €1.84. Therefore, HAEMATO AG's PE Ratio for today is 9.45.

Good Sign:

HAEMATO AG stock PE Ratio (=9.59) is close to 10-year low of 8.73

During the past 13 years, HAEMATO AG's highest PE Ratio was 24.36. The lowest was 8.13. And the median was 13.76.

HAEMATO AG's EPS (Diluted) for the six months ended in Jun. 2023 was €0.44. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €1.84.

As of today (2024-05-05), HAEMATO AG's share price is €17.40. HAEMATO AG's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was €1.28. Therefore, HAEMATO AG's PE Ratio without NRI ratio for today is 13.55.

During the past 13 years, HAEMATO AG's highest PE Ratio without NRI was 27.01. The lowest was 8.07. And the median was 14.56.

HAEMATO AG's EPS without NRI for the six months ended in Jun. 2023 was €0.61. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was €1.28.

During the past 12 months, HAEMATO AG's average EPS without NRI Growth Rate was 184.70% per year.

During the past 13 years, HAEMATO AG's highest 3-Year average EPS without NRI Growth Rate was 38.20% per year. The lowest was -33.10% per year. And the median was -2.00% per year.

HAEMATO AG's EPS (Basic) for the six months ended in Jun. 2023 was €0.44. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was €1.85.

Back to Basics: PE Ratio


HAEMATO AG PE Ratio Historical Data

The historical data trend for HAEMATO AG's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HAEMATO AG PE Ratio Chart

HAEMATO AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.37 At Loss At Loss 18.13 10.35

HAEMATO AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss 18.13 At Loss 10.35 At Loss

Competitive Comparison of HAEMATO AG's PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, HAEMATO AG's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HAEMATO AG's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HAEMATO AG's PE Ratio distribution charts can be found below:

* The bar in red indicates where HAEMATO AG's PE Ratio falls into.



HAEMATO AG PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

HAEMATO AG's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=17.40/1.842
=9.45

HAEMATO AG's Share Price of today is €17.40.
For company reported semi-annually, HAEMATO AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1.84.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


HAEMATO AG  (HAM:HAEK) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


HAEMATO AG PE Ratio Related Terms

Thank you for viewing the detailed overview of HAEMATO AG's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


HAEMATO AG (HAM:HAEK) Business Description

Traded in Other Exchanges
Address
Lilienthalstrasse 5c, Schonefeld, DEU, D-12529
HAEMATO AG is a Germany based pharmaceutical company. It provides pharmaceuticals for the care of chronically ill people. The firm is engaged in the sale of generic and EU (European countries) import drugs. It is focused on patented and non-patented medicinal products. The company product portfolio includes human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), neurology, oncology, rheumatology, and urology. Geographically, it operates only in Germany.

HAEMATO AG (HAM:HAEK) Headlines

No Headlines